ClinicalTrials.gg
TerminatedNCT03110575Updated Feb 6, 2025Results posted

12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients

A Phase 3 interventional study of TNX-102 SL in PTSD, sponsored by Tonix Pharmaceuticals, Inc.. Terminated at 32 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-06.

Sponsored by Tonix Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
Stopped early due to inadequate separation on primary efficacy endpoint in the lead-in HONOR study, TNX-CY-P301

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
190
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States — 341 open to participants now, 404 under way, 18 of them phase 3. Stress Disorders, Post-Traumatic · United States.

Enrollment
265th of 1,491
190 · median 65
Started
2017
with 73 others
Phase 3
64 of 1,664
8 open now
Registered
755th of 1,664
by date

Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, this one is the 265th largest by enrollment of the 1,491 interventional ones that give a count, is one of 74 that started in 2017, is one of 64 in phase 3, and was the 755th registered.

Stress Disorders, Post-Traumatic

2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 603 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

341 of the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States are open now. Recruiting first, the newest first:

336 more — sign in →

All 341 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, extension trial designed to evaluate safety over 12 additional weeks of TNX-102 SL therapy taken daily at bedtime for the treatment of PTSD. Patients recruited into this trial are those who have successfully completed the double-blind lead-in study.

Read the detailed description

The study will consist of 5 study visits, including Screening/Baseline Visit 1 (Day 0, which is anticipated to be the same visit as the last visit on double-blind treatment), a phone visit after 2 weeks of treatment, and in-clinic visits after 4, 8, and 12 weeks of treatment.

The primary objective of the study is to evaluate the safety of TNX-102 SL tablets taken daily at bedtime over an additional 12 weeks in patients with PTSD who have completed a double-blinded lead-in study.

The secondary objective of the study is to evaluate the efficacy of TNX-102 SL tablets taken daily at bedtime over an additional 12 weeks in patients with PTSD who have completed a double-blinded lead-in study.

03

Conditions studied

  • PTSD

Keywords

  • TNX-102 SL
  • Bedtime
  • Sublingual
  • 3-month
  • Safety
  • Efficacy
  • PTSD
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has completed the final treatment study visit of the lead-in study and remained compliant with the lead-in protocol and study treatment.
  • The patient has provided written to participate in this extension protocol.
  • Female patients of continue to agree to practice one of the medically acceptable methods of detailed in the lead-in study.

Exclusion criteria

Exclusion Criteria:

  • None.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
190 participants (actual)

Study arms

  • Experimental
    TNX-102 SL

    2 x TNX-102 SL, 2.8 mg tablets taken daily at bedtime for 12 weeks

    Drug: TNX-102 SL

Interventions

  • 2 x TNX-102 SL, 2.8mg tablets taken daily at bedtime for 12 weeks

    Also known as: cyclobenzaprine HCl

06

What researchers measure

Primary outcomes

  1. Incidence of Newly Emergent Adverse Events of TNX-102 SL Tablets Taken Daily at Bedtime Over an Additional 12 Weeks in Patients With PTSD Who Have Completed a Double-blinded lead-in Study

    Adverse events will be coded using the latest version of the Medical Dictionary for Regulatory Activities (MedDRA) and will be summarized overall and by preferred term and system organ class.

    Time frame: 12 weeks

Secondary outcomes

  1. Change From Both Baselines in the Total Clinician Administered PTSD Scale for DSM-5 (CAPS-5) Score

    The CAPS-5 symptom severity 1-week recall version will be administered by qualified and trained clinicians. Score ranges from 0 to 80 with lower scores indicating less severe PTSD symptoms.

    Time frame: Day 1 of TNX-CY-P301 (Week -12 of TNX-CY-P303), Day 1 of TNX-CY-P303, Week 12 of TNX-CY-P303

07

Results

Posted Feb 6, 2025

Participant flow

Participant flow — Overall Study
MilestonePlacebo - TNX-102 SLTNX-102 SL - TNX-102 SL
Started9793
Completed6867
Not completed2926

Outcome measures

PrimaryIncidence of Newly Emergent Adverse Events of TNX-102 SL Tablets Taken Daily at Bedtime Over an Additional 12 Weeks in Patients With PTSD Who Have Completed a Double-blinded lead-in Study

Adverse events will be coded using the latest version of the Medical Dictionary for Regulatory Activities (MedDRA) and will be summarized overall and by preferred term and system organ class.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Incidence of Newly Emergent Adverse Events of TNX-102 SL Tablets Taken Daily at Bedtime Over an Additional 12 Weeks in Patients With PTSD Who Have Completed a Double-blinded lead-in Study
ParticipantsPlacebo - TNX-102 SLTNX-102 SL - TNX-102 SL
Incidence of Newly Emergent Adverse Events of TNX-102 SL Tablets Taken Daily at Bedtime Over an Additional 12 Weeks in Patients With PTSD Who Have Completed a Double-blinded lead-in Study6240
SecondaryChange From Both Baselines in the Total Clinician Administered PTSD Scale for DSM-5 (CAPS-5) Score

The CAPS-5 symptom severity 1-week recall version will be administered by qualified and trained clinicians. Score ranges from 0 to 80 with lower scores indicating less severe PTSD symptoms.

Time frame:
Day 1 of TNX-CY-P301 (Week -12 of TNX-CY-P303), Day 1 of TNX-CY-P303, Week 12 of TNX-CY-P303
Reported as:
Least squares mean · units on a scale
Change From Both Baselines in the Total Clinician Administered PTSD Scale for DSM-5 (CAPS-5) Score
units on a scalePlacebo - TNX-102 SLTNX-102 SL - TNX-102 SL
Change from TNX-CY-P301 baseline-24.5 ± 2.43-24.2 ± 2.64
Change from TNX-CY-P303 baseline-6.2 ± 1.63-6.2 ± 1.78

Adverse events

Collected over 12 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo - TNX-102 SL0/97 (0%)0/97 (0%)49/97 (50.5%)
TNX-102 SL - TNX-102 SL0/93 (0%)0/93 (0%)19/93 (20.4%)
Most frequent other events
Most frequent other events
EventPlacebo - TNX-102 SLTNX-102 SL - TNX-102 SL
Hypoaesthesia OralGastrointestinal disorders29/9712/93
GlossodyniaGastrointestinal disorders9/972/93
SomnolenceNervous system disorders9/978/93
Paraesthesia oralGastrointestinal disorders7/972/93
Product Taste AbnormalProduct Issues6/974/93

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo - TNX-102 SLTNX-102 SL - TNX-102 SLTotal
Mean36.5 ± 8.1936.1 ± 7.8536.3 ± 8.01
Sex: Female, Male
Sex: Female, Male(Participants)Placebo - TNX-102 SLTNX-102 SL - TNX-102 SLTotal
Female15621
Male8287169
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo - TNX-102 SLTNX-102 SL - TNX-102 SLTotal
Hispanic or Latino181634
Not Hispanic or Latino7977156
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo - TNX-102 SLTNX-102 SL - TNX-102 SLTotal
American Indian or Alaska Native246
Asian437
Native Hawaiian or Other Pacific Islander325
Black or African American172239
White6456120
More than one race527
Unknown or Not Reported246
Region of Enrollment
Region of Enrollment(participants)Placebo - TNX-102 SLTNX-102 SL - TNX-102 SLTotal
United States9793190
08

Study locations

32 sites
  • Phoenix
    Phoenix, Arizona 85032, United States
  • Rogers
    Rogers, Arkansas 72758, United States
  • Beverly Hills
    Beverly Hills, California 90210, United States
  • Glendale
    Glendale, California 91206, United States
  • Oakland
    Oakland, California 94607, United States
  • Oceanside
    Oceanside, California 92056, United States
  • Orange
    Orange, California 92868, United States
  • Riverside
    Riverside, California 92506, United States
  • San Diego
    San Diego, California 92123, United States
  • San Diego
    San Diego, California 92161, United States
  • Temecula
    Temecula, California 92591, United States
  • Colorado Springs
    Colorado Springs, Colorado 80910, United States
  • Jacksonville
    Jacksonville, Florida 32256, United States
  • Lake City
    Lake City, Florida 32607, United States
  • Lauderhill
    Lauderhill, Florida 33319, United States
  • Tampa
    Tampa, Florida 33609, United States
  • Atlanta
    Atlanta, Georgia 30341, United States
  • New Bedford
    New Bedford, Massachusetts 02740, United States
  • Flowood
    Flowood, Mississippi 39232, United States
  • Las Vegas
    Las Vegas, Nevada 89102, United States
  • Berlin
    Berlin, New Jersey 08009, United States
  • Cedarhurst
    Cedarhurst, New York 11516, United States
  • New York
    New York, New York 10128, United States
  • Canton
    Canton, Ohio 44718, United States
  • Cincinnati
    Cincinnati, Ohio 45219, United States
  • Dayton
    Dayton, Ohio 45417, United States
  • Oklahoma City
    Oklahoma City, Oklahoma 73103, United States
  • Charleston
    Charleston, South Carolina 29407, United States
  • Austin
    Austin, Texas 78754, United States
  • Dallas
    Dallas, Texas 75231, United States
  • Houston
    Houston, Texas 77098, United States
  • San Antonio
    San Antonio, Texas 78229, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Jul 2018, 13 months.

Results were first posted in Feb 2025, 6 years 6 months after primary completion. A results delay was requested in Sep 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2017
First posted
Apr 12, 2017
StartActual
Jun 20, 2017
Primary completionActual
Jul 27, 2018
CompletionActual
Jul 27, 2018
Results delay requested
Sep 9, 2019
Results first posted
Feb 6, 2025
Last update
Feb 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03110575
Collaborators
Premier Research Group plc
Responsible party
Sponsor
First posted
Apr 12, 2017
Start date
Jun 20, 2017
Primary completion
Jul 27, 2018
Completion
Jul 27, 2018
Results posted
Feb 6, 2025
Last update
Feb 6, 2025

Study contacts

Denise Bedoya
study director · Premier Research Group plc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclobenzaprine

Start the discussion